HEPSERA: profile and news

Healthcare: At a Glance - Roche Hepatitis Drug Thrust Onto Front ... Mar 3, 2006
As well as making Pegasys a frontline drug, NICE has recommended Gilead Sciences' Hepsera (adefovir dipivoxil), which slows the progression of CHB, as a ... - International News Service,

Gilead Sciences Welcomes Guidance From Nice On Treatment Of ... Feb 22, 2006
...announced that the National Institute for Health and Clinical Excellence (NICE) has endorsed the use of its oral antiviral drug Hepsera® (adefovir dipivoxil ... - Medical News Today (press release),

Novartis/Idenix: Entering Hepatitis B Market Feb 9, 2006
...opportunity awaits telbivudine as none of the three antiviral therapies already available, namely GlaxoSmithKline's Zeffix, Gilead's Hepsera (adefovir dipivoxil ... - International News Service,

Gilead Sciences Announces Fourth Quarter and Full Year 2005 ... Jan 30, 2006
...its US launch in August of 2004, as well as continued strong product sales for AmBisome(R) (amphotericin B) liposome for injection and Hepsera(R) (adefovir ... - Genetic Engineering News,

Novartis/Idenix: entering hepatitis B market Feb 7, 2006
...opportunity awaits telbivudine as none of the three antiviral therapies already available, namely GlaxoSmithKline's Zeffix, Gilead's Hepsera (adefovir dipivoxil ... - Pharmaceutical Business Review

Truvada Boosts Gilead's Revenue Jan 30, 2006
...from a year ago, while product sales climbed for the ninth straight quarter as a result of the HIV drug Truvada and growth for the hepatitis B treatment Hepsera ... - TheStreet.com

Gilead 4th-qtr profit doubles but stock falls Jan 30, 2006
Fourth-quarter sales of antifungal drug Ambisome rose 1 percent to $55.6 million and sales of hepatitis B drug Hepsera rose 43 percent to $51.2 million. ... - Reuters

GILEAD SCIENCES INC Jan 11, 2006
Sales of Hepsera, GILD's treatment for hepatitis B, rose 58% on the year, to name another product. Most of GILD revenue stems from HIV treatment products. ... - Reuters

Tenofovir works as well for HBV in coinfected with 3TC resistance ... Jan 27, 2006
Currently, two other oral anti-HBV drugs are approved in the United States - adefovir (Hepsera) and entecavir (Baraclude) - although only adefovir currently ... - Aidsmap,

Five-Year Data Evaluating Long-Term Therapy with Hepsera(R) for ... Nov 14, 2005
Gilead Sciences (Nasdaq:GILD) today presented data describing the sustained efficacy and safety of its oral antiviral drug Hepsera(R) (adefovir dipivoxil) for ... - Genetic Engineering News,

Five-Year Data Evaluating Long-Term Therapy with Hepsera for ... Nov 14, 2005
Nov 14, 2005--Gilead Sciences (Nasdaq:GILD) today presented data describing the sustained efficacy and safety of its oral antiviral drug Hepsera(R) (adefovir ... - PharmaLive.com (press release),

Zoek in het archief Nov 14, 2005
...( BW)(CA-GILEAD-SCIENCES)(GILD) Five-Year Data Evaluating Long-Term Therapy with Hepsera for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Presented ... - Netherlands Corporate News,

Clinical Trials Update: Dec. 6, 2005 Dec 6, 2005
This study is designed to evaluate the safety and antiviral activity of tenofovir disoproxil fumarate (DF) compared to Hepsera for the treatment of HBeAg ... - Atlanta Journal Constitution (subscription),

Metabasis Comments on Positive Data Reported at AASLD Late-Breaker ... Nov 15, 2005
...the pradefovir 30mg QD cohort achieved a 5.02 log(10) drop in viral titers from baseline compared to a 3.66 log(10) drop in the 10 mg QD Hepsera(R) (adefovir ... - PR Newswire (press release),

Metabasis Comments on Positive Data Reported at AASLD Late-Breaker ... Nov 15, 2005
30mg QD cohort achieved a 5.02 log(10) drop in viral titers from baseline compared to a 3.66 log(10) drop in the 10 mg QD Hepsera® (adefovir dipivoxil) group ... - Yahoo! News (press release)

Valeant Pharmaceuticals Presents Positive Interim Data on ... Nov 15, 2005
...undetectable HBV DNA (less than 400 c/mL) was significantly greater for patients receiving pradefovir compared to those receiving Hepsera (adefovir dipivoxil ... - Business Wire (press release),

Valeant Pharmaceuticals Presents Positive Interim Data on ... Nov 15, 2005
...undetectable HBV DNA (less than 400c/mL) was significantly greater for patients receiving pradefovircompared to those receiving Hepsera (adefovir dipivoxil) at ... - Finanzen.net,

Home Depot, Analog Devices, Saks, JC Penney, more Nov 14, 2005
Gilead Sciences Inc. (GILD) said that data from a five-year study indicates that its hepatitis B drug, Hepsera, showed sustained efficacy and safety. ... - Investor's Business Daily (subscription)

Montgomery & Co. LLC Announces Investment Opinion: Initiates ... Dec 1, 2005
It sells five drugs, Truvada, Viread and Emtriva, for HIV treatment; AmBisome, for fungal infections; and Hepsera for chronic hepatitis B infection. ... - Business Wire (press release),

Novartis: hepatitis B pill better than standard drug Nov 14, 2005
...(GILD.O: Quote, Profile, Research) called Hepsera. All four drugs are nucleoside analogues, which disrupt the enzyme that reproduces the hepatitis B virus. ... - Reuters

Tenofovir More Effective than Adefovir for Long-Term Treatment of ... Nov 23, 2005
Berlin, Germany. Adefovir dipivoxil (Hepsera) is a nucleotide analogue that treats lamivudine resistant hepatitis B virus. Tenofovir ... - DG News

Long-Term Adefovir Dipivoxil Effective for HIV and Treatment ... Nov 21, 2005
SAN FRANCISCO, CA -- November 21, 2005 – Long-term use of adefovir dipivoxil (Hepsera) as an add-on to lamivudine appears effective in hard-to-treat ... - DG News

Gilead's Half-Empty Pipeline Nov 21, 2005
But as King points out, approval of Viread for hepatitis B will likely cannibalize sales of Gilead's existing hep B drug, Hepsera. ... - Forbes

Gilead Sciences Announces Third Quarter 2005 Financial Results Oct 18, 2005
...its US launch in August of 2004, as well as continued strong product sales for AmBisome(R) (amphotericin B) liposome for injection and Hepsera(R) (adefovir ... - Business Wire (press release),

Gilead profits spike on HIV drug sales Oct 18, 2005
...older HIV drug, to Truvada. The company's hepatitis B drug, Hepsera, saw sales jump 58% to $46.9 million. Royalties earned on its ... - MarketWatch

UPDATE 1-HIV drug sales lift Gilead quarterly profit 58 pct Oct 18, 2005
Third-quarter sales of antifungal drug Ambisome rose 10 percent to $54.7 million and sales of hepatitis B drug Hepsera rose 58 percent to $46.9 million. ... - Reuters

Gilead earnings up on HIV/AIDS drug operations Oct 18, 2005
...earlier. Sales of Hepsera, the company's treatment for chronic hepatitis B, rose to $46.9 million from $29.7 million a year earlier. ... - San Jose Mercury News,

Gilead Beats Consensus; HIV Drugs Driving Growth Oct 19, 2005
Its hepatitis B drug, Hepsera, which had sales of $46.9 million for the quarter, marking a 58 percent increase from the $29.7 million recorded a year earlier ... - BioWorld Online (subscription),

Gilead Sciences Announces Initiation of Phase III Clinical Program ... Jul 19, 2005
..."Gilead has already brought to market Hepsera, an important antiviral for the treatment of chronic hepatitis B," said Norbert Bischofberger, PhD, Executive ... - Genetic Engineering News

Gilead Sciences Announces Second Quarter 2005 Financial Results Jul 19, 2005
Sales of Hepsera(R) (adefovir dipivoxil 10 mg) totaled $45.8 million for the second quarter of 2005, a 64 percent increase from $28.0 million in the second ... - Genetic Engineering News

New leader for an expanding market Jul 11, 2005
The hepatitis B market has been dominated by GlaxoSmithKline’s Epivir-HBV and Gilead Sciences Inc.’s Hepsera. According to Datamonitor ... - Med Ad News (subscription)

Metabasis reports on drug study Jul 20, 2005
The San Diego biotechnology company said the drug, pradefovir, is similar to a leading hepatitis treatment already on the market, Gilead Sciences' Hepsera. ... - San Diego Union Tribune

Gilead qtr profit up 76 pct on HIV drug Jul 19, 2005
Second-quarter sales of antifungal drug Ambisome rose 2 percent to $56.2 million and sales of hepatitis B drug Hepsera rose 64 percent to $45.8 million. ... - Washington Post

Metabasis Comments on Positive Data Reported by Valeant ... Jul 19, 2005
The Phase 2 study consists of five treatment groups: pradefovir -- 5, 10, 20 and 30 mg/day, and Hepsera® (adefovir dipivoxil) -- 10 mg/day, with an overall ... - Yahoo News (press release)

Gilead Walks Past Estimates Jul 19, 2005
...said it has begun enrolling patients in a phase 3 trial evaluating its oral tenofovir DF in chronic hepatitis B. The company already sells Hepsera for the same ... - TheStreet.com

$525M Gets Emtriva Interest From Emory For Gilead, Royalty Pharma Jul 19, 2005
One study will enroll 300 patients, while the other will enroll 240 patients, who will be randomized between tenofovir DF and Gilead's Hepsera. ... - BioWorld Online (subscription)

Manager trumpets Gilead, Symantec Jul 27, 2005
Gilead's treatment for hepatitis B, Hepsera, generated more than $100 million last year. It's working on a treatment for hepatitis C. ... - MSN Money

UPDATE 1-Gilead quarter profit up 76 pct on HIV drug sales Jul 19, 2005
Sales of antifungal drug Ambisome rose 2 percent to $56.2 million and sales of hepatitis B drug Hepsera rose 64 percent to $45.8 million. - Reuters

Drug May Work for HBV-Related Cirrhosis Jul 6, 2005
Oncol Rep 2005 Jun;13(6):1159-63. 2. Hepatitis Neighborhood. HBV Medications: Intron-A, Epivir HBV, Hepsera & Baraclude. Available ... - Hepatitis Neighborhood

Pegasys Tops Epivir For HBV Jul 14, 2005
Viral drug resistance is another complex problem, Lok writes, particularly with the use of nucleoside analogs such as Epivir or Hepsera (adefovir dipivoxil). ... - Hepatitis Neighborhood <**results**>

Long-Term Hepsera Treatment Shows Benefit in HBV: Research Jun 15, 2005
Patients prescribed Hepsera as a therapy for hepatitis B (HBV) over the long term may find it beneficial, report doctors in a recently unveiled clinical trial. ... - Hepatitis Neighborhood

Presse économique / Santé / Médical BIOWIRE2K Jun 30, 2005
...(Nasdaq:GILD) a annoncé ce jour que les données à 144 semaines portant sur l'efficacité et la tolérabilité de son antiviral oral Hepsera(R) (adéfovir ... - Le Figaro

Data Evaluating Long-Term Therapy with Hepsera for Hepatitis B ''e ... Jun 29, 2005
...(Nasdaq:GILD) today announced that data through 144 weeks supporting the efficacy and tolerability of its oral antiviral drug Hepsera(R) (adefovir dipivoxil ... - Business Wire (press release)

FOSTER CITY, Calif.--(BUSINESS WIRE)--June 29, 2005--Gilead Jun 30, 2005
...oggi che i dati rilevati nel corso di 144 settimane che provano l’efficacia e la tollerabilità del suo farmaco orale antivirale Hepsera(R) (adefovir ... - Companynewsgroup (Comunicados de prensa)

Evidence Backs New Treatments for Hepatitis B Jun 29, 2005
MD, of the Henry Dunant Hospital in Athens and colleagues from the Adefovir Dipivoxil 438 Study Group reported the benefit of Hepsera (adefovir dipivoxil) in ... - MedPage Today

Tests compare drugs for hepatitis B Jun 29, 2005
A separate hepatitis B study found a third drug, Foster City, California-based Gilead Sciences 's Hepsera, is effective only with continued use. ... - Reuters AlertNet

Studies compare hepatitis B drugs Jun 30, 2005
In a separate hepatitis B study it was found that a third drug, Gilead Sciences, Hepsera, was effective only with continued use. ... - News-Medical.net

Chronic Viral Hepatitis a Billion Dollar Market Untapped Jun 29, 2005
However, the development of the first two antivirals, GSK's Zeffix (lamivudine) with $1 million in 2004 and Gilead's Hepsera (adefovir dipivoxil) has led to ... - PharmaLive.com (press release)

Chronic viral hepatitis: B is for billions Jun 10, 2005
However, the development of the first two antivirals, GSK's Zeffix (lamivudine) and Gilead's Hepsera (adefovir dipivoxil) has led to considerable growth in the ... - Pharmaceutical Business Review

Cash In on the Future of Science Jun 29, 2005
...of 2000, Gilead began phase 3 clinical trials of what would become two of its most important products, Viread (for HIV infection) and Hepsera (for hepatitis B ... - Motley Fool

Dyax Announces Results from Two Clinical Trials of DX-88 and ... Jul 1, 2005
...(Nasdaq: GILD) recently announced that data through 144 weeks supporting the efficacy and tolerability of its oral antiviral drug Hepsera® (adefovir dipivoxil ... - Financial News USA (press release),